Skip to main content

Table 4 Summary of findings for the main outcomes using the GRADE methodology

From: Anti-hypertensive drugs deprescribing: an updated systematic review of clinical trials

Certainty assessment Number of patients Effect Certainty
№ of studies Study design Risk of bias Inconsistency Indirectness Imprecision Other considerations Anti-hypertensives withdrawal Anti-hypertensives continuation Relative (95% CI) Absolute (95% CI)  
Number of patients with systolic blood pressure < 150 mmHg (mean follow up: 12 weeks)
1 [21] Open label RCT Serious Not serious Not serious Not serious None 229/265 (86.4%) 236/269 (87.7%) RR 0.98 (0.92 to 1.05) 18 fewer per 1000 (70 fewer to 44 more) MODERATE
Quality of life (mean follow up: 12 weeks; assessed with: EQ-5D-5L Index)
1 [21] Open label RCT Serious Not serious Not serious Not serious None 260 263 MD 0.01 lower (0.03 lower to 0.01 higher) MODERATE
Frailty (assessed with: Frailty Index)
1 [21] Open label RCT Serious Not serious Not serious Not serious None 282 287 MD 0.00003 lower (0.0005 lower to 0.005 higher) MODERATE
Cardiovascular risk
1 [22] Open label RCT Serious Not serious Not serious Not serious None 492 575 MD 0.1 higher (0.4 lower to 0.7 lower) MODERATE
  1. Abbreviations: CI Confidence interval; RCT randomized controlled trial; RR Risk ratio; MD Mean difference